David C Griffith (D C Griffith)

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 4

Top Topics

Multidrug Resistant

Klebsiella Pneumoniae

Top Venues

Antimicrobial agents and chemotherapy

This page only lists publications with an associated author ORCID identifier.

Publications

María Patricia Hernández-Mitre, Steven C Wallis, Elizabeth E Morgan, Michael N Dudley, Jeffery S Loutit, David C Griffith, Jason Alexander Roberts
A phase I, randomized, double-blind, placebo-controlled, ascending single- and multiple-dose study of the pharmacokinetics, safety, and tolerability of oral ceftibuten in healthy adult subjects. Antimicrobial agents and chemotherapy (2023)
Sujata M Bhavnani, Michael Trang, David C Griffith, Olga Lomovskaya, J P Hammel, J S Loutit, S K Cammarata, M N Dudley, Paul G Ambrose, Christopher M Rubino
Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints. Antimicrobial agents and chemotherapy (2022)
David C Griffith, Elizabeth E Morgan, Michael N Dudley, Jeffery S Loutit
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Biapenem in Healthy Adult Subjects. Antimicrobial agents and chemotherapy (2021)
Mojgan Sabet, Ziad Tarazi, David C Griffith
In Vivo Activity of QPX7728, an Ultrabroad-Spectrum Beta-Lactamase Inhibitor, in Combination with Beta-Lactams against Carbapenem-Resistant Klebsiella pneumoniae. Antimicrobial agents and chemotherapy 64 (11) (2020)